Femasys Inc. (NASDAQ: FEMY) shares were stationery Thursday, as the biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of products, announced the appointment of James Liu, M.D., as Chief Medical Officer. Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®.
“With an exciting product pipeline and a culture focused on execution of the development and commercialization of differentiated women’s health procedures, Femasys stands apart in the industry,” said Dr. Liu. “I’m excited to join the company as it advances a new wave of potentially transformative therapies to meet the many areas of unmet needs for patients specifically in reproductive health.”
Dr. Liu received his M.D. from Ohio State University School of Medicine, completed a residency in obstetrics and gynecology at University of Rochester-Strong Memorial Hospital and undertook a fellowship in Reproductive Endocrinology at University of California, San Diego. Dr. Liu is Professor Emeritus at Case Western Reserve University after serving for over 21 years as the Chairman, Department of Obstetrics and Gynecology, University Hospital Health System and the Chair, Department of Reproductive Biology, Case Western Reserve University. He also served as the Division head, Reproductive Endocrinology and Infertility at the University of Cincinnati.
FEMY shares closed Wednesday night to 96 cents
